FDA 483 - Otsuka Pharmaceutical Development & Commercialization, Inc - May 19, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Otsuka America Pharmaceutical, Inc. in Rockville, MD, a specification developer, revealed significant deficiencies in their quality system. Observations included inadequate design verification for products like BreathTek UPT collection bags and Pranactin-Citric, insufficient validation of device software, and failures in establishing and implementing corrective and preventive actions. Additionally, the firm did not perform quality audits at defined intervals or with sufficient frequency.
- Inspection Date
- May 19, 2017
- Product Type
- Drugs
ID · 39edbca6-da40-46e2-9927-8ecfdc44b721